Since the anti-cancer mechanisms of metformin involve direct and indirect AMPK-dependent and -independent inhibition of mammalian target of rapamycin (mTOR) [11,32], we focused on the changes in mTOR and downstream ERK or S6 phosphorylation. This evidence concerns the gene MTOR and cancer.